Key points are not available for this paper at this time.
As the clinical prevalence of antibiotic-resistant bacteria rises, the effectiveness of antibacterial drugs has been greatly reduced, hence, it is essential to create novel antibacterial materials for combating bacterial infections. In recent years, antimicrobial peptides (AMPs) have demonstrated significant promise in addressing infections caused by bacteria, but as a natural product, they are limited in terms of activity and stability, and cannot exert their full effect. The conjugation of peptide-based biomaterials makes up for this shortcoming, and the antimicrobial activity is also improved, which also lays the foundation for its clinical application. This review aims to introduce the current progress of AMPs-based biomaterials in the treatment of multidrug-resistant bacterial infections, covering the topics from their sources to the delivery of treatment in combining biomaterial AMPs. In addition, its therapeutic advantages, including synergistic treatment, improved stability and effectiveness, and high biocompatibility, are also discussed. Finally, the current situation and prospects of AMP-based biomaterials for multidrug-resistant bacterial infections are summarized.
Yuan et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: